The FDA is reviewing Casgevy for potential use in children with sickle cell disease as young as 5. Some reports suggest Casgevy may be effective in preventing sickle cell crises in children, while others indicate that a different sickle cell drug was scrapped due to safety concerns. The status of Casgevy's approval is unclear, with some outlets reporting FDA approval and others mentioning a priority review.